North America Sleep Apnea Diagnostics Market

Market Introduction

The sleep apnea diagnostics market in North America is further segmented into the US, Canada, and Mexico. The US held the largest share of the North America sleep apnea diagnostics market in 2021. In the US, the growth of the market is accelerated with high prevalence of sleep apnea and rising awareness about sleep apnea and its risk factors. Further, sleep apnea is one of the major health issues in the U.S. and is one of the most common sleep disorders. The market growth is also accelerated with increasing importance of sleep testing in adults and pediatric population. The American Sleep Apnea Association estimates that 38,000 people in the United States die each year from heart disease with sleep apnea as a complicating factor. Additionally, increasing demand for sleep apnea devices and presence of key players in the market also fuel the market growth. Key players in the market now focus on the development of new devices for sleep apnea. For instance, ResMed, one of the key market players, offers wide range of devices for sleep apnea such as AirMini, AirSense 10 CPAP and AirSense 10 Elite. The company also sponsors various studies for the treatment of sleep apnea. The National Center on Sleep Disorders Research (NCSDR), Division of Lung Diseases of the NHLBI, coordinated with various government authority such as NIH for sleep and circadian research.

North American region is highly affected due to the outbreak of the Covid-19 pandemic. Countries such as the US and Canada reported the highest numbers of COVID-19 positive cases. The US-registered highest number of deaths due to the COVID-19 pandemic. The chaotic situation was created in the medical industry across the countries, increased demand for diagnosing and therapeutic devices have dramatically increased in the hospitals. For instance, demand for ventilators, respirators, and in vitro diagnostic (IVD) tests has risen drastically in the hospitals across the countries. On the other hand, demand for personal protective kits has significantly gone up. The FDA has increased its efforts to support the health of people and has imposed several guidelines and for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. So increased demand in other categories have considerably hamper the sleep apnea diagnostics market. Thus, market is likely to be slower in COVID-19.

North America Sleep Apnea Diagnostics Strategic Insights

Strategic insights for the North America Sleep Apnea Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Sleep Apnea Diagnostics Report Scope

North America Sleep Apnea Diagnostics Regional Insights

The geographic scope of the North America Sleep Apnea Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The sleep apnea diagnostics market in North America is expected to grow US$ 177.12 million in 2021 to US$ 259.45 million by 2028; it is estimated to grow at a CAGR of 5.6% from 2021 to 2028. Obstructive sleep apnea (OSA) is a common disorder, categorized by the repetitive, complete or partial closure of the upper airway during sleep. This airway is helpful in the fragmentation of sleep and oxygen desaturation. The disorder causes significant morbidity, especially in terms of impairment of daytime functioning and the impact this has on the quality of life. The recent indication from controlled trials is the proof of the efficiency of oral appliance in controlling OSA in up to 50.0% of patients, including patients with more severe forms of OSA. According to a survey conducted by the investment firm, Needham & Company, over one-third of OSA tests were conducted in patients' homes in 2018, up from 15% in 2013. As a result, companies are concentrating their efforts on the development of home-care sleep apnea equipment. Due to the rising usage of the polysomnography (PSG) device in the various regions, the need for improved and technologically advanced polysomnography (PSG) device for the diagnosis of OSA has surged substantially, driving the sleep apnea diagnostics market.

Key Market Segments

In terms of product, the polysomnography (PSG) device segment accounted for the largest share of the North America sleep apnea diagnostics market in 2021. In term of end user, hospitals and sleep laboratories segment held a larger market share of the sleep apnea diagnostics market in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the sleep apnea diagnostics market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are ResMed, Inc.; Nihon Kohden Corporation LLC; SOMNOmedics GmbH; Cleveland Medical Devices Inc.; Koninklijke Philips N.V.; Natus Medical Incorporated; Itamar Medical Ltd.; Compumedics Limited; Drive DeVilbiss International; and Cadwell Industries Inc. among others.

Reasons to buy report

• To understand the North America sleep apnea diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for North America sleep apnea diagnostics market
• Efficiently plan M&A and partnership deals in North America sleep apnea diagnostics market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America sleep apnea diagnostics market
• Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

North America Sleep Apnea Diagnostics Market Segmentation

North America Sleep Apnea Diagnostics Market – By Product

• Polysomnography (PSG) Device
• Home Sleep Testing Devices
• Oximeter

• FingerTip Oximeter
• Handheld Oximeter
• Wrist-worn Oximeter
• Tabletop Oximeter

• Actigraphy Monitoring Device
• Sleep Apnea Screening Device

North America Sleep Apnea Diagnostics Market – By

End User

• Hospitals and Sleep Laboratories
• Home Care Settings

North America Sleep Apnea Diagnostics Market – By

Country

• US
• Canada  
• Mexico     

North America Sleep Apnea Diagnostics Market – Companies Mentioned

• ResMed Inc.
• Nihon Kohden Corporation LLC
• SOMNOmedics GmbH
• Cleveland Medical Devices Inc. 
• Koninklijke Philips N.V.
• Natus Medical Incorporated
• Itamar Medical Ltd.
• Compumedics Limited
• Drive DeVilbiss International
• Cadwell Industries Inc.